Company / Capital Expenditures
Vivos Therapeutics, Inc. Capital Expenditures History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$568.0K
FY2025
5-year range
$120.0K / $2.4M
FY2021-FY2025
Trend
-29.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures has declined for 3 consecutive years, from $2M in FY2022 to $568,000 in FY2025.
Based on SEC 10-K filings.
$568,000 in FY2025 with a 5-year CAGR of +26.5%.
Declined from $924,000 to $568,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -38.1%
- 5-Year CAGR
- +26.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- Vivos Therapeutics, Inc.'s capital expenditures has declined for 3 consecutive years.
- 5-year CAGR of +26.5%, indicating consistent growth.
- In FY2025, capital expenditures decreased 29.3% year-over-year.
- Peak capital expenditures was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $568.0K | -29.3% |
| FY2024 | $803.0K | -13.1% |
| FY2023 | $924.0K | -61.4% |
| FY2022 | $2.4M | +1896.7% |
| FY2021 | $120.0K | -31.7% |
| FY2020 | $175.6K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026